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Abstract Monoamine reuptake inhibitors increase brain-
derived neurotrophic factor (BDNF) activity, and this
growth factor is regarded as an interesting target for devel-
oping new antidepressant drugs. The aims of this study were
to evaluate whether monoaminergic reuptake inhibition
increases BDNF in vivo and in vitro as predicted by the
neurotrophic hypothesis of depression, and whether triple
reuptake inhibition has a superior BDNF response compared
to dual reuptake inhibition. Twenty-one days of oral treat-
ment (30 mg/kg) with the dual serotonin/noradrenaline
reuptake inhibitor duloxetine or the triple serotonin/nor-
adrenaline/dopamine reuptake inhibitor DOV 216,303 re-
stored BDNF protein levels in the rat hippocampus, which
were initially decreased due to injection stress. The prefron-
tal cortex contained increased BDNF levels only after DOV
216,303 treatment. In vitro, neither duloxetine nor DOV
216,303 altered intracellular BDNF levels in murine HT22
neuronal cells. In contrast, BDNF release was more effec-
tively decreased following treatment with DOV 216,303 in
these cells. In rat C62B astrocytomas, both antidepressants
increased intracellular BDNF levels at their highest nontoxic
concentration. C62B astrocytomas did not release BDNF,
even after antidepressant treatment. Increased BDNF levels
support the neurotrophic hypothesis of depression, but our
findings do not clearly evidence that the BDNF response
after triple reuptake inhibitors is more effective than after
dual reuptake inhibitors. Moreover, the data suggest that the
role of BDNF in neurons and astrocytes is complex and
likely depends on factors including specificity of cell types
in different brain regions, cell–cell interactions, and differ-
ent mechanisms of action of antidepressants used.
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Introduction
According to the neurotrophic hypothesis of depression, the
pathophysiology of depression is caused by reduced neuro-
genesis, i.e., proliferation and survival of new neurons
(Duman et al. 2000; Jacobs et al. 2000). Trophic factors,
such as brain-derived neurotrophic factor (BDNF), have
been implicated in animal hippocampal neurogenesis, in
particular survival (Lee et al. 2002; Sairanen et al. 2005).
In the postmortem brain of suicide victims, hippocampal
BDNF protein levels are decreased (Karege et al. 2005),
and chronic stress in animals decreased BDNF mRNA
(Smith et al. 1995) and protein (Xu et al. 2006, 2002) in
the hippocampus. In contrast, BDNF mRNA (Calabrese et
al. 2010; Nibuya et al. 1995) and protein (Balu et al. 2008;
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Hodes et al. 2010; Xu et al. 2006, 2002) were increased after
long-term administration of several types of monoaminergic
antidepressants, such as selective serotonin reuptake inhib-
itors (SSRIs), serotonin and noradrenaline reuptake inhib-
itors (SNRIs), and tricyclic antidepressants (TCAs), which
primarily act as an SNRI. Likewise, BDNF protein was
increased in the hippocampus of depressed patients who
were treated with such antidepressants (Chen et al. 2001).
Moreover, the same antidepressants increased proliferation
and survival of neurons in the hippocampus in animals
(Czeh et al. 2007; Khawaja et al. 2004; Madsen et al. 2000;
Sairanen et al. 2005; Santarelli et al. 2003; Xu et al. 2006).
It should be noted that not only the hippocampus is
implicated in the pathophysiology of depression as BDNF
protein is increased in the frontal cortex of rats after treat-
ment with different monoaminergic antidepressants (Balu et
al. 2008; Calabrese et al. 2010, 2007; Cooke et al. 2009;
Hodes et al. 2010; Mannari et al. 2008). Traditionally, the
focus of CNS research is on neurons, but in the last decade,
glial cells have received more attention. Studies have
reported a decrease in glial cells in the hippocampus (Muller
et al. 2001) and prefrontal cortex (Cotter et al. 2002) of
patients with depression and in an animal model of chronic
stress (Czeh et al. 2007), while chronic antidepressant treat-
ment increased the glial numbers in both structures (Czeh et
al. 2007; Malberg et al. 2000; Santarelli et al. 2003).
Evidence is accumulating that BDNF has antidepressant
properties. For instance, intrahippocampal injections of
BDNF have antidepressant effects in rodent models (learned
helplessness) and tests (forced swimming test) of depressive
symptoms (Gourley et al. 2008; Shirayama et al. 2002).
Along similar lines, it has been demonstrated with an siRNA
approach, using an adenovirus, that deletion of BDNF in the
dentate gyrus of mouse hippocampus was sufficient to at-
tenuate antidepressant effects of the SSRI citalopram (Adachi et
al. 2008). In conditional BDNF knockout mice with a selective
BDNF gene deletion in the forebrain, the antidepressant action
of the TCA desipramine was attenuated (Monteggia et al. 2007).
Thus, BDNF plays a pivotal role in the molecular pathways
involved in depression, as well as in the mechanisms underlying
antidepressant activity. Therefore, BDNF is regarded as a prom-
ising target for studying pathophysiological processes in depres-
sion and for developing new antidepressant drugs.
A potential drug development strategy is to further opti-
mize existing drugs known to modulate central BDNF, such
as SSRIs and SNRIs. An example is the development of
triple serotonin, noradrenaline, and dopamine reuptake
inhibitors, such as DOV 216,303 (Skolnick et al. 2003).
Demonstration of a superior BDNF response after triple
reuptake inhibitor treatment, compared to dual or single
reuptake inhibitor treatment, could provide a mechanistic
rationale for the hypothesis that triple reuptake inhibitors
might be more clinically efficacious.
In the present study, we first investigated the in vivo BDNF
response in the hippocampus and prefrontal cortex of rats after
chronic treatment with the dual reuptake inhibitor duloxetine
and the triple reuptake inhibitor DOV 216,303. In addition,
the BDNF response (synthesis and release) of both neurons
and astrocytes was studied in vitro by using HT22 hippocam-
pal neuronal cells and C62B astrocytoma cells. The aims of
this study were to evaluate: (1) whether monoaminergic inhi-
bition increases BDNF in vivo and in vitro as predicted by the
neurotrophic hypothesis of depression, and (2) whether a
triple reuptake inhibition approach has a superior BDNF
response compared to a dual reuptake inhibitor approach.
Material and Methods
Drugs
The dual reuptake inhibitor duloxetine HCl and the triple
reuptake inhibitor DOV 216,303-HCl were manufactured
by a Sepracor contractor and characterized internally. Both
compounds were dissolved in H2O.
In Vivo Experiments
Animals
For the in vivo study, 40 healthy male Wistar rats were used
(2 months old, 225–250 g; Harlan Laboratories, Dublin, VA,
USA). Upon arrival, the animals were acclimatized for
12 days. All rats were housed two animals per cage with
food and water ad libitum, controlled ambient temperature,
and a 12-h light/dark cycle (lights on, 6 a.m.; lights off,
6 p.m.). The animals were evenly divided into four groups
(n010): control (no treatment), vehicle treatment, duloxe-
tine treatment, or DOV 216,303 treatment. All experimental
procedures were in accordance with governmental guide-
lines and approved by the Board of Registration in Medicine
(BRM) Institutional Animal Care and Use Committee
(BRM protocol number 03-32).
Pharmacological Treatment
On day 13, the treatment period was started at a dose of 30 mg/
kg/day duloxetine, 30 mg/kg/day DOV 216,303 or vehicle
(H2O). These dosages have already been shown to exert antide-
pressant potential (Breuer et al. 2008; Katoh et al. 1995). The
compounds or vehicle were orally administered (by gavage),
daily, for 21 consecutive days between 10 a.m. and 2 p.m.
Control rats received neither treatment nor handling during the
entire treatment period. One animal in the duloxetine group
suddenly died on day 4 of the treatment period without any
preceding signs of sickness or discomfort (remaining n09).
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Sample Collection
Twenty-four hours after the last treatment, all animals were
sacrificed by CO2; after which, the animals were immedi-
ately decapitated, and the prefrontal cortex and hippocam-
pus (bilateral) were isolated and snap frozen in liquid
nitrogen. All samples were stored at −80°C.
Tissue Homogenization
Frozen brain samples were weighed and transferred into 2-ml
screw cap microcentrifuge tubes. For homogenization of the
prefrontal cortex and hippocampus, T-PER tissue protein ex-
traction reagent (Pierce Biotechnology, Thermo Scientific,
Pittsburgh, PA, USA) was used and supplemented with
1 mM PMSF, 25 U/ml Benzonase nuclease, and complete
mini-EDTA-free protease inhibitor cocktail tablets according
to manufacturer's instructions. Corresponding volumes of
T-PER reagent (500 μl/50 mg tissue) and glass disruption
beads (Research Products International Corp., Mt Prospect,
IL, USA) (≈0.25 ml beads/50 mg tissue) were added. The
tubes were kept on ice for 2 min and homogenized by use of a
FastPrep-24 instrument (MP Biomedicals, Solon, OH, USA).
Homogenization was followed by centrifugation for 30 min at
4°C and 13,000 g. The supernatant was transferred to new
tubes, aliquoted, acid treated (see BDNF immunoassay), and
stored at −80°C until used for ELISA.
In Vitro Experiments
Cell Lines
C62B rat astrocytoma (obtained and licensed from Johns
Hopkins University, Rockville, MD, USA) and HT22 murine
hippocampal cells (obtained and licensed from Salk Institute,
La Jolla, CA, USA) were grown on 6-well plates from BD
BioCoat Cellware (BD Biosciences, San Jose, CA, USA).
Cells were plated at a seeding density of 2.5×105 cells/well
for C62B (passage 25) and 1×105 cells/well for HT22 (pas-
sage 10). Both cell lines were cultured in Dulbecco's modified
Eagle's medium (American Type Culture Collection (ATCC),
Rockville, MD, USA), supplemented with 1 % penicillin/
streptomycin (Mediatech, Manassas, VA, USA) and 10 %
heat-inactivated fetal bovine serum (ATCC). Cells were main-
tained at 37°C in a humidified atmosphere of 5 % CO2 (C62B
cells) or 10 % CO2 (HT22 cells).
Pharmacological Treatment
Pharmacological treatment was started 16 or 40 h after
seeding for 48- and 24-h treatment, respectively. All cells
were harvested 64 h after seeding at 80–90 % confluency.
For treatment, the culture medium was replaced by fresh
medium containing duloxetine (1 or 10 μM) or DOV
216,303 (1, 10, or 50 μM). Of note, higher concentrations
up to 100 μM were also tested, but they were found to be
toxic (duloxetine was toxic at concentrations of ≥50 μM,
while DOV 216,303 was toxic at 100 μM). Toxicity was
observed by eye, 100 % free floating cells in the medium
compared to 0 % free floating cells at lower drug concen-
trations. For the negative controls, the culture medium was
replaced by fresh medium containing vehicle (H2O). All in
vitro experiments were performed in triplicate.
Cell Harvesting and Protein Isolation
Cells were harvested by use of M-PER mammalian protein
extraction reagent (Pierce Biotechnology, Thermo Scientif-
ic, Pittsburgh, PA, USA) and supplemented with 1 mM
PMSF (Fluka, Sigma-Aldrich, St Louis, MO, USA), 25 U/
ml Benzonase nuclease (Novagen, EMD Chemicals, San
Diego, CA, USA), and complete mini-EDTA-free protease
inhibitor cocktail tablets (Roche, Nutley, NJ, USA) accord-
ing to manufacturer's instructions.
Culture medium was aspirated, and cells were washed with
phosphate buffered saline PBS; after which, 200 μl M-PER
reagent was added. After 5 min gently shaking at room tem-
perature, lysates were collected, transferred to microcentrifuge
tubes, incubated on ice for 5 min, gently vortexed, and centri-
fuged at 4°C for 10 min at 13,000 g. For extracellular BDNF
measurements, medium was collected and centrifuged for
10 min at 4°C and 13,000 g. The supernatant was transferred
to new tubes, and protein concentration was measured by use
of the DC protein assay (Bio-Rad, Hercules, CA, USA)
according to manufacturer's instructions. Samples were
aliquoted, acid treated (see BDNF immunoassay), and stored
at −80°C until used for ELISA.
BDNF Immunoassay
Preceding the ELISA, acid treatment of the samples is recom-
mended for the measurement of BDNF. For this purpose,
samples were diluted five times in Dulbecco's PBS, followed
by acidification (15 min at room temperature) with 1 N HCl to
reach pH<3.0 and a neutralization step by adding 1 N NaOH
to bring the pH to approximately 7.6. After acid treatment, all
samples were stored at −80°C until used for ELISA.
Detection of total BDNF protein was performed by use of
the BDNF Emax immunoassay system (Promega, Madison,
WI, USA) according to supplier's protocol. All samples
were assayed in triplicate. To calculate total BDNF protein
in cell lysates (picogram BDNF per milligram total protein),
ELISA absorbance readouts were corrected for dilution
factor and total protein levels. In brain tissue samples,
absorbance readouts were corrected for dilution factor and
recalculated to nanogram BDNF per gram wet tissue weight
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as described previously (Balu et al. 2008; Prickaerts et al.
2006). Cell growth medium samples were only corrected for
the dilution factor.
Data Analysis and Statistics
In vivo data were analyzed using one-way ANOVA with
compound concentration as a fixed factor and Dunnett's post
hoc test. Prefrontal cortex data from one animal in the
control group, qualified as an outlier, were discarded from
the total data set (remaining n09). In vitro data were analyzed
by two-way ANOVA with compound concentration and du-
ration of treatment as factors. In case of statistical significance,
we performed Bonferroni post hoc contrast comparisons to
compare treatments with their corresponding control (vehicle)
as well as to compare the two treatment durations for each
compound concentration. Data are presented as means+SEM,
and significance was set at P<0.05. Statistical Package for the
Social Sciences (SPSS) 16.0 (SPSS Inc., Chicago, IL, USA)
was used for statistical analysis.
Results
In Vivo Experiments
Chronic treatment of animals with duloxetine or DOV
216,303 had no effect on body weight gain of animals com-
pared to vehicle-treated and untreated control rats (data not
shown). Figure 1 summarizes the effects of daily oral vehicle,
duloxetine, or DOV 216,303 injections on total BDNF levels
in the hippocampus and frontal cortex 24 h after the last
administration. There was a significant difference in BDNF
levels between groups in the hippocampus (F3,35011.89;
P<0.001). Post hoc analysis revealed that daily administration
with vehicle alone (1.45±0.05 ng BDNF/g wet wt) led to a
significant reduction in hippocampal BDNF levels compared
to the untreated control group (1.91±0.13 ng BDNF/g wet wt;
P<0.01; Fig. 1a). Both compounds significantly reversed this
oral injection-induced decrease in BDNF levels (duloxetine,
2.19±0.10 ng BDNF/g wet wt; P<0.001; DOV 216,303,
2.22±0.11 ng BDNF/g wet wt; P<0.001; Fig. 1a). In the
prefrontal cortex, a tendency was found for differences be-
tween groups (F3,3502.62; 0.05<P<0.1), which was
explained by an increase in BDNF after DOV 216,303 treat-
ment (1.89±0.09 ng BDNF/g wet wt) compared to vehicle
(1.56±0.10 ng BDNF/g wet wt; P<0.05; Fig. 1b). No injec-
tion effect on BDNF levels was found in the prefrontal cortex.
In Vitro Experiments
Figure 2 summarizes the results for 24- and 48-h treatment of
HT22 hippocampal cells with duloxetine or DOV 216,303.
Treatment with duloxetine did not alter intracellular BDNF
levels in the hippocampal HT22 cells (F2,1100.67, ns;
Fig. 2a), but reduced extracellular BDNF (F2,1105.41;
P<0.05; Fig. 2c). Post hoc analysis showed that 10 μM
duloxetine significantly decreased extracellular BDNF levels
after 48-h treatment (35.90±1.34 pg BDNF/ml medium) as
compared with vehicle treatment (91.52±18.46 pg BDNF/ml
medium; P<0.05). Treatment with DOV 216,303 did not alter
intracellular BDNF levels (F3,1602.34, ns; Fig. 2b), but
reduced extracellular BDNF levels (F3,1609.55; P<0.001)
at higher DOV 216,303 concentrations after 24 h (vehicle,
67.32±8.93 pg BDNF/ml medium; 10 μM, 47.38±1.43 pg
BDNF/ml medium, 0.05<P<0.1; 50 μM, 44.01±0.76 pg
BDNF/ml medium, P<0.05; Fig. 2d) and at lower concentra-
tions after 48 h (vehicle, 91.52±18.46 pg BDNF/ml medium;
1 μM, 54.20±2.54 pg BDNF/ml medium, P<0.01; 10 μM,
49.92±0.46 pg BDNF/ml medium, P<0.001; 50 μM, 42.05±
1.60 pg BDNF/ml medium, P<0.001; Fig. 2d).
Figure 3 summarizes the results for treatment of C62B
astrocytoma cells with both monoaminergic reuptake inhib-
itors. Both compounds changed BDNF levels (duloxetine,
F2,11071.98, P<0.001; DOV 216,303, F3,16056.30, P<
0.001). Post hoc analysis showed that both compounds
significantly increased intracellular BDNF levels at their
highest nontoxic dose (10 μM duloxetine for 24 h, 16.43±
1.25 vs. 10.00±0.28 pg BDNF/mg total protein, P<0.001;
10 μM duloxetine for 48 h, 20.19±0.77 vs. 10.79±0.56 pg
BDNF/mg total protein, P<0.001; 50 μM DOV 216,303 for
24 h, 15.79±0.80 vs. 10.00±0.28 pg BDNF/mg total pro-
tein, P<0.001; 50 μM DOV 216,303 for 48 h, 19.85±0.82
vs. 10.79±0.56 pg BDNF/mg total protein, P<0.001). In
addition, 48-h treatment at these concentrations yielded
significantly higher intracellular BDNF levels compared to
24-h treatment (10 μM duloxetine 24 vs. 48 h, P<0.01;
50 μM DOV 216,303 24 vs. 48 h, P<0.001; Fig. 3b). No
extracellular BDNF was detected in the astrocytoma cell
cultures.
Discussion
The dual reuptake inhibitor duloxetine has antidepressant
properties, as found with acute treatment in rodents in the
forced swimming test (Katoh et al. 1995). However, to our
knowledge, there is only indirect evidence that chronic
treatment with duloxetine has antidepressant properties, as
it was found to have an anxiolytic effect in mice after
chronic treatment (10 mg/kg twice a day for 28 days), but
not acute treatment, reflecting clinical experiments with
antidepressants in general (Troelsen et al. 2005). The triple
reuptake inhibitor DOV 216,303 displayed antidepressant
properties in the rat olfactory bulbectomy model when given
orally for 14 days at a dose of 20 mg/kg (Breuer et al. 2008),
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although these data could not be replicated in a similar study
(Prins et al. 2011). Our data show a decrease in BDNF levels
in the hippocampus of animals that received vehicle by oral
gavage as compared to the animals that were untreated
controls. Gavage treatment and handling are stressful (Van
der Heyden et al. 1997) and likely the cause of decreased
BDNF levels, which can be ameliorated with duloxetine and
DOV 216,303. The antidepressants increased BDNF in the
hippocampus to higher levels than in the vehicle-treated
group, but not the nontreated group.
Direct comparisons have shown that the BDNF response
seen in the frontal cortex after dual reuptake inhibition was
not necessarily observed with single reuptake inhibitors
(Calabrese et al. 2007; Cooke et al. 2009; Hodes et al.
Fig. 1 Male Wistar rats were chronically treated for 21 consecutive days
with duloxetine, DOV 216,303, or vehicle (H2O). Control animals re-
ceived neither treatment nor handling. The hippocampus (a) and prefron-
tal cortex (b) were dissected 24 h after the last treatment, and total BDNF
protein levels were measured. Both compounds reversed the reduction in
hippocampal BDNF levels due to chronic oral administration. Prefrontal
cortex BDNF levels increased after DOV 216,303 treatment only. Data
are shown as mean values + SEM. *P<0.05; **P<0.01; ***P<0.001
Fig. 2 Hippocampal HT22
cells were treated for 24 or 48 h
with duloxetine or DOV
216,303. Intracellular BDNF
levels were not altered by
duloxetine or DOV 216,303
(a, b). Extracellular BDNF
levels were significantly
reduced after treatment with
duloxetine or DOV 216,303,
especially after 48-h treatment
(c, d). Data are presented as
mean values + SEM.
*P<0.05; **P<0.01;
***P<0.001
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2010). This underlines the view that dual substrate inhibition
may be more effective than single. Here, an increase in BDNF
was observed in the prefrontal cortex only after treatment with
DOV 216,303, but not duloxetine, suggesting an even more
effective BDNF response of triple versus dual reuptake inhi-
bition. When directly comparing BDNF levels in the frontal
cortex to the hippocampus, it can be noted that after chronic
treatment with antidepressants like duloxetine, the BDNF
protein response in the frontal cortex can be present without
any effect in the hippocampus (Balu et al. 2008; Calabrese et
al. 2007; Cooke et al. 2009). In the current study, 30 mg/kg
duloxetine was apparently high enough to restore BDNF
levels in the hippocampus, but was ineffective in the prefron-
tal cortex. The present lack of an effect of duloxetine on cortex
BDNF levels may be due to differences in dissection of the
prefrontal and frontal cortex, with different areas of the cortex
being present in the two different studies.
Among glial cells, astrocytes are of particular interest as
they provide structural, metabolic, and trophic support for
neurons (Ransom et al. 2003). Trophic support implies that
astrocytes are a source of trophic substances regulating
neurogenesis (Song et al. 2002), although they also may
contribute to neurogenesis when retaining stem cell-like
properties (Horner and Palmer 2003). Support for a role of
BDNF produced by astrocytes in the pathophysiology of
depression comes from in vivo experiments using conditional
BDNF knockout mice with a selective BDNF gene deletion in
the forebrain. These studies found that astrocyte-specific BDNF
deletion resulted in similar depression-like behavior and attenu-
ation of the antidepressant response to desipramine as with
neuron-specific BDNF deletion (Monteggia et al. 2007). In
vitro, fluoxetine increased BDNFmRNA expression in primary
rat astrocytes within 2 h (Mercier et al. 2004) and in primary
mouse astrocytes after 24-h exposure (Allaman et al. 2011).
However, 24-h serotonin exposure did not affect BDNF expres-
sion in primary mouse astrocytes (Allaman et al. 2011). Yet,
monoamine, including serotonin, administration to cultured
neonatal astrocytes induced the release of BDNF (Juric et al.
2006). In our study, the undifferentiated C62B rat astrocytoma
cells were capable of synthesizing BDNF after treatment with
duloxetine or DOV 216,303. The lack of BDNF in the media
indicates that these cells did not release BDNF which suggests
that the role of BDNF in astrocytes may be dependent on the
specific type of cell and its interactions with other cells (e.g.,
neurons), as well as differences in mechanism of action of the
antidepressants used.
In a recent study, the TCA imipramine induced differen-
tiation of cultured rat hippocampal neural stem cells into
serotonergic neurons, and this effect was blocked by BDNF
siRNA, suggesting that BDNF synthesis and release is nec-
essary (Peng et al. 2008). In the present study, duloxetine
and DOV 216,303 were able to decrease extracellular
BDNF levels in undifferentiated murine HT22 hippocampal
neuronal cells, which are known to express the serotonin
transporter, the dopamine, and norepinephrine receptors
(Heiser et al. 2002; Schmidt et al. 2001; Shimada et al.
2010). As we expected an increase in BDNF release after
antidepressant treatment, this indicates that, as in astrocytes,
similar factors are of relevance in determining the net effect
of an antidepressant on neuronal BDNF signaling. Of note,
there is currently no evidence at hand of a possible physio-
logical function for this decrease in extracellular BDNF
levels in our neuronal cells. Nevertheless, the overall effects
of DOV 216,303 on the BDNF response in HT22 cells, i.e.,
its broader range of effective concentrations, might indicate
that DOV 216,303 is more effective than duloxetine with
regard to the BDNF response in these cells. However, the
efficacy is determined by many factors ranging from the
presence of monoamine transporters, the occupancy efficiency
of the compounds (duloxetine binds better to the serotonin and
noradrenaline transporter than DOV 216,303), and the avail-
able cell-type specific signal transduction machinery (e.g.,
DOV 216,303 has an effect on dopamine) to the onset of action
(Lengyel et al. 2008). It has to be noted that duloxetine was
Fig. 3 C62B astrocytoma cells were treated for 24 or 48 h with
duloxetine or DOV 216,303. Both compounds significantly increased
intracellular BDNF levels at their highest nontoxic dose (10 μM for
duloxetine and 50 μM for DOV 216,303) (a, b). At these
concentrations, intracellular BDNF levels were significantly higher
after 48-h treatment compared to 24-h treatment. No extracellular
BDNF was detected in the astrocytes cell cultures. All bar graphs
represent mean values + SEM. *P<0.05; **P<0.01; ***P<0.001
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able to increase intracellular BDNF levels at lower concentra-
tions (10 μM) than DOV 216,303 (50 μM) in astrocytic C62B
cells. This would suggest dual reuptake inhibition to be more
effective than triple reuptake inhibition in this type of cells.
This once more shows that potential differences in efficacy of
dual and triple reuptake inhibitors are dependent on the specific
biological system being studied.
Our in vivo and in vitro findings as described above
indicate that the BDNF response after antidepressant treat-
ment is more complex than predicted by the neurotrophin
hypothesis of depression. Some animal and human studies
failed to confirm the neurotrophin hypothesis of depression.
In human postmortem brain, the effects of antidepressants
on proliferation were inconclusive (Boldrini et al. 2009) or
not detectable (Lucassen et al. 2010). In animal models of
depression, elimination of neurogenesis by focal hippocam-
pal irradiation blocks the antidepressant action of monoam-
inergic drugs in some (e.g., novelty-suppressed feeding), but
not all (forced swimming test) behavioral tests (David et al.
2009). These data suggest neurogenesis-dependent and in-
dependent mechanisms of action of antidepressants. This
also warrants further research on the exact contribution of
BDNF in the pathophysiology of depression and its antide-
pressant action (Chourbaji et al. 2010).
BDNF is produced as a precursor called proBDNF, which
can be proteolytically cleaved to yield mature BDNF (Lee et
al. 2001).Whether antidepressants change the production and/
or release of proBDNF and mature BDNF is not clear yet, but
the few studies that addressed this issue suggest that antide-
pressants have a limited effect on proBDNF levels (Calabrese
et al. 2010, 2007; Mannari et al. 2008). Given the biologically
distinct roles of both BDNF forms, with proBDNF linked to
apoptotic pathways and long-term depression and mature
BDNF linked to enhanced plasticity (Lu et al. 2005), the
effects of duloxetine and DOV 216,303 on proteolytic pro-
cessing of proBDNF are an interesting issue that may warrant
future investigation. In this study, however, we could not
distinguish between proBDNF and mature BDNF as the anti-
body from the ELISAwe used binds both.
Taken together, our in vivo data show that, in the hippo-
campus, BDNF levels can be rescued after chronic treatment
with duloxetine or DOV 216,303. In the prefrontal cortex,
DOV 216,303, but not duloxetine, increases basal BDNF
levels. In addition, our in vitro data indicate that intracellular
BDNF levels can increase in astrocytes with these mono-
aminergic reuptake inhibitors. These findings are in accor-
dance with the neurotrophic hypothesis of depression.
However, the in vitro data indicate that the effects on BDNF
release and, consequently, BDNF signaling are more com-
plex. Together with a lack of a clear in vivo effect in the
prefrontal cortex by duloxetine, these data suggest that the
eventual net effect on BDNF signaling of a monoaminergic
reuptake inhibitor depends on multiple factors, potentially
including the mechanism of action of the antidepressant, the
particular brain region and its cell–cell interactions. It
remains to be elucidated how monoaminergic reuptake
inhibitors influence BDNF levels. Increased monoamines
activate their respective G protein-coupled receptors, thus
activating signaling cascades (e.g., IP3/DAG and cAMP/
PKA signaling) that may ultimately result in activation of
the transcription factor CREB and BDNF transcription. The
routine measurement of in vivo total BDNF or in vitro total
intracellular BDNF may not be sufficient to predict the overall
neurogenic or antidepressant profile of potential antidepressants.
Moreover, evidence suggests that the link between BDNF and
its antidepressant efficacy is not as straightforward as was
initially anticipated. For instance, studies with BDNF heterozy-
gous mice or with mice having a hippocampal knockdown of
BDNF failed to show depressive-like behavior, though such
knockdown of BDNF attenuates antidepressant efficacy
(Adachi et al. 2008; Monteggia et al. 2007). In addition, it has
been shown that BDNF signaling in the ventral tegmental area-
nucleus accumbens system exerts prodepressant effects in con-
trast to the general consensus linking BDNF to antidepressant
action (Berton et al. 2006; Eisch et al. 2003). This suggests that
the actions of BDNF are highly dependent on the brain region of
interest. Some of the data presented in this study hint towards a
more effective BDNF response to DOV 216,303, which is
“hypothesis generating”, as it suggests that triple inhibitors
may possess a more robust neurogenic and, eventually, antide-
pressant profile. However, sufficient proof to justify such claim
is lacking, and this needs to be substantiated with dedicated in
vitro and in vivo studies that systematically compare the effects
of DOV 216,303 and duloxetine as well as further mono, dual,
and triple monoamine reuptake inhibitors. These studies should
also measure intra- and extracellular BDNF and distinguish
between proBDNF andmature BDNF. Such an approach would
result in a composed BDNF response in different standardized
settings for monoaminergic or even nonmonoaminergic drugs.
This could be used as an indication for their antidepressant
potential, which should be verified using a broad battery of
behavioral tests.
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